Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma

Ki vehet részt

• Age ≥ 18 years, regardless of sex
• Confirmed diagnosis of follicular lymphoma (FL), or histopathologically confirmed CD20-positive marginal zone lymphoma (MZL), including extranodal marginal zone lymphoma (MALT), splenic marginal zone lymphoma (SMZL), and nodal marginal zone lymphoma (NMZL),or confirmed diagnosis of indolent mantle cell lymphoma (MCL)
• Patients with a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
• Confirmed diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia
• Presence of indications for treatment of indolent B-cell lymphoma
• No prior systemic antitumor therapy for lymphoma
• ECOG-PS score 0-2
• Essentially normal bone marrow hematopoietic function, with routine blood tests as follows: white blood cell count >3000/uL, absolute neutrophil count ≥1.5 × 10\^9/L (use of granulocyte colony-stimulating factor is allowed), platelet count ≥75 × 10\^9/L (transfusion to reach this minimum platelet count is allowed), and hemoglobin ≥9.0 g/dL (prior red blood cell transfusion or use of recombinant human erythropoietin is allowed). If peripheral blood abnormalities are caused by lymphoma involvement of the bone marrow or spleen, neutrophils≥1.0 × 10\^9/L and platelets≥50 × 10\^9/L are acceptable (the investigator may determine at his/her discretion whether enrollment is appropriate)
• Normal function of major organs:; Hepatic function: serum bilirubin ≤2.0 × ULN; serum ALT and AST ≤2.5 × ULN; Renal function: creatinine clearance >30 mL/min
• Expected survival≥3 months as judged by the investigator; Voluntary written informed consent signed before trial screening

Ki nem vehet részt

• Major surgery within the past 30 days (excluding lymph node biopsy)
• Current or prior other malignancy, unless curative treatment has been performed and there has been no evidence of recurrence or metastasis within the past 5 years
• Other serious medical conditions that would affect this study (e.g., uncontrolled diabetes, gastric ulcer, or other serious cardiopulmonary diseases). The investigator has the authority to make this determination
• Severe or uncontrolled infection
• Allergy to the study drug; Patients considered unsuitable for enrollment by the investigator
• Hepatic or renal dysfunction unrelated to lymphoma: alanine aminotransferase (ALT) >3 times the upper limit of normal, aspartate aminotransferase (AST) >3 times the upper limit of normal, total bilirubin (TBIL) >2 times the upper limit of normal, or serum creatinine >1.5 times the upper limit of normal
• Lymphoma involvement of the central nervous system or transformation to a higher-grade lymphoma
• Clinically manifest central nervous system dysfunction
• Pregnant or lactating women, or women of childbearing potential who have not used contraceptive measures